DOCSLIB.ORG

Anesthesia and Tocolytic / Uterotonic Therapy in Obstetrics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anesthesia and Tocolytic / Uterotonic Therapy in Obstetrics First part of presentation: tocolytic therapy … a professional challenge • anesthesia: rarely involved in decision-making • expert knowledge essential ¾ basic pharmacological principles of such a therapy - potential side effects and complications ¾ taking care of pregnant women under tocolysis - secondary preterm Cesarean delivery Second part of presentation: uterotonic therapy … a professional challenge • anesthesia: always involved in decision-making ¾ Cesarean delivery … teamwork: essential component ¾ manual removal of placenta of safe patient care • expert knowledge as basis of a team approach ¾ basic pharmacological principles of such a therapy - potential side effects and complications ¾ taking care of pregnant women at risk of PPH Factors determining uterine tone Uterus contractility 2+ •Caintracellular as determining factor ¾ influx from extracellular compartment - slow voltage-dependent calcium channels ¾ release/reuptake from sarcoplasmatic reticulum • myosin light chain kinase activity as determining factor 2+ ¾ Ca dependent myosin phosphorylation Uterine contraction: contractile protein actomyosin Vercauteren M et al, Acta Anaesthesiol Scand 2009 Drugs affecting uterine contractility Tocolytic substances • β-adrenergic drugs ® ® ¾ fenoterol (Partusisten ), hexoprenaline (Gynipral ) • Calcium channel blockers ® ¾ nifedipine (Adalat ) • Oxytocin antagonists ® ¾ atosiban (Tractocile ) • Prostaglandin synthesis inhibitors (COX-1, COX-2) ® ® ¾ indomethacin (Indocid , Elmetacin ) • Magnesium sulphate • Nitroglycerine Vercauteren M et al, Acta Anaesthesiol Scand 2009 Drugs affecting uterine contractility Uterotonic substances → induction/augmentation of labor → prevention/treatment of postpartum hemorrhage (PPH) • Oxytocin receptor (OXTR) agonists ® ® ¾ oxytocin (Syntocinon ), carbetocin (Pabal ) • Prostaglandins ® ® ¾ PGE2/sulproston (Nalador , Propess ) ® ¾ PGE1/misoprostol (Cytotec ) • Ergot alkaloids ® ¾ methylergometrine or methylergonovine (Methergin ) Vercauteren M et al, Acta Anaesthesiol Scand 2009 A close look at patients receiving tocolytic therapy Patients in preterm labor at risk of • preterm birth <37 completed weeks of gestation ¾ preterm birth rate Europe 2005 6.2% (95%CI 5.8–6.7) ¾ preterm birth rate worldwide 2005 9.6% (95%CI 9.1–10.1) Neonatal mortality (<7 days of life) • unrelated to congenital malformations ∼ 28% Neonatal morbidity extending to later life • cerebral palsy, sensory deficits, learning disabilities ¾ risk of life-long care if birth <28 weeks ∼ 10% • respiratory distress syndrome Beck S et al, Bull World Health Organ 2010 Prevention of prematurity as therapeutic goal Implementation of beneficial clinical strategies • fetal lung maturation: corticosteroid administration ¾ 21 studies, 4269 infants RR (95%CI) - respiratory distress syndrome 0.66 (0.59-0.73) - cerebroventricular haemorrhage 0.54 (0.43-0.69) - neonatal death 0.69 (0.58-0.81) Roberts D et al, Cochrane Database Syst Rev 2006 • in utero transfer to a specialized care facility (NICU) Improving neonatal survival - <26 weeks of gestation Sweden 1990-92 +3% per day Finnström O et al, Acta Paediatr 1997 Revisiting the issues of tocolytic efficacy and indications Metaanalysis of trials of tocolyis comparing • nifedipine with β-adrenergic therapy OR (95%CI) ¾ efficacy in delaying birth at least 48 h 1.52 (1.03-2.24) ¾ efficacy in delaying birth over 34 wks 1.87 (1.11-3.15) ¾ treatment discontinuation 0.12 (0.05-0.29) Tsatsaris V et al, Obstet Gynecol 2001 Prophylactic tocolytic therapy for suspected fetal distress • β-adrenergic drugs vs no treatment RR (95%CI) ¾ no improvements in FHR abnormalities 0.26 (0.13-0.53) • β-adrenergic drugs vs MgSO4 ¾ reduction in uterine activity 0.07 (0.00-1.10) Kulier R et al, Cochrane Database Syst Rev 2009 Risks and complications associated with tocolytic therapy β-adrenergic therapy • tachycardia, arrhythmia, myocardial ischemia • pulmonary edema (≤24 hrs after discontinuation) ¾ risk factors OR (95%CI) - spontaneous preterm labor 10.9 (1.3-90) - tocolytic therapy 4.3 (2.3-8.4) - corticosteroid therapy 2.3 (1.3-4.0) - chorioamnionitis 2.7 (1.1-6.5) Ogunyemi D, Eur J Obstet Gynecol Reprod Biol 2007 ¾ fluid retention and metabolic effects -ADH ↑, aldosterone ↑, glucagon ↑, insulin ↑ Vercauteren M et al, Acta Anaesthesiol Scan 2009 Atosiban (oxytocin antagonist): a safer tocolytic ? Multinational multicenter double-blind randomized trial • preterm labor at 23 – 33 wks (n = 733) •atosiban vsβ-agonists (ritodrine, salbutamol, terbutaline) • at least 18 hrs up to 48 hrs Effectiveness • undelivered after 48 hrs (%) 88.1 : 88.9 after 7 days (%) 79.9 : 77.6 • age at delivery (mean [SD]) 35.8 [3.8] : 35.5 [4.1]* Safety • adverse cardiovascular events (%) 8.3 : 81.2* • treatment discontinuation (%) 1.1 : 15.4* Worldwide atosiban vs beta-agonists study group, Br J Obstet Gynaecol 2001 Atosiban: can we afford it ? Metaanalysis: 3 double-blinded, placebo-controlled trials • start of tocolysis within 48 hrs of admission ® ¾ atosiban vs β-agonist fenoterol (Partusisten ) • cost per case German hospital drug purchase costs + treatment of associated adverse events Outcomes • efficacy (RR (95%CI)) 0.99 (0.94–1.04) • cost savings with atosiban (G-DRG) ¾ 18 hrs of atosiban tocolysis (€) 226 per case ¾ 48 hrs of atosiban tocolysis (€) 71 per case • incidence of adverse events ↓ 6 : 16 items* Wex J at al, BMC Pregnancy and Childbirth 2009 2nd part of presentation focus on the postpartum period scientific drawing of a fetus in utero (1510-13) Leonardo da Vinci (1452 – 1519) Having a close look at uterotonic therapy Out at last … after vaginal birth or Cesarean delivery • stimulation of uterine contraction (active management) • prevention of uterine atony and PPH Oxytocin receptor (OXTR) agonists • oxytocin (Syntocinon®), carbetocin (Pabal®) Prostaglandins ® •PGE2/sulproston (Nalador ) ® •PGE1/misoprostol (Cytotec ) Ergot alkaloids • methylergometrine (Methergin®) Risks and complications of uterotonic therapy Oxytocin (Syntocinon®) • hemodynamic side effects ¾ vasodilation, hypotension, tachycardia, nausea, vomiting ¾ hypovolemia, cardiac disease: cardiac arrest • hormonal side effects ¾ fluid retention, hyponatremia Carbetocin (Pabal®) • more hemodynamic stability ? • less hormonal side effects ? • a single 100 μg IV bolus as effective and more reliable than a standard continuous infusion of oxytocin … ? Boucher M et al, J Perinatol 1998 Dosis sola facit venenum Poison is in everything, and no thing is without poison. The dosage makes it either a poison or a remedy. Paracelsus (1493–1541) Oxytocin: minimum effective intravenous bolus dose ? Randomized, single-blinded study in healthy patients • elective Cesarean delivery under spinal anesthesia (n=40) Oxytocin requirements response rate (%) 100 •ED90 0.35 IU (95%CI 0.18–0.52) 80 • estimated response rates 60 40 ¾ ED97.1 0.5 IU 20 ¾ ED 1.0 IU 100 0 0 0.2 0.4 0.6 0.8 1.0 Carvalho JCA et al, Obstet Gynecol 2004 oxytocin dose (IU) Oxytocin: minimum effective intravenous bolus dose ? Randomized double-blind placebo-controlled dose-range trial • elective Cesarean delivery under spinal anesthesia (n=75) Oxytocin bolus dose uterine tone (0-10) • 0, 0.5, 1, 3, or 5 IU 10 8 Uterine tone (UT) 6 2 min • 0 (no UT) – 10 (optimal UT) 4 3 min 2 6 min • after 2, 3, 6, and 9 min 0 9 min •ED50/ED90 not determined 0 0.5 1.0 3.0 5.0 Butwick AJ et al, Br J Anaesth 2010 oxytocin dose (IU) Oxytocin: minimum effective intravenous bolus dose ? Randomized, single-blinded study • C section for labor arrest under epidural anesthesia (n=30) Oxytocin requirements* probability of uterine response 1 •ED90 2.99 IU (95%CI 2.32–3.67) 0.8 • loading dose 0.6 0.4 0.2 * biased coin up-down sequential 0 allocation scheme 0.5 1.0 1.5 2.0 2.5 3.0 3.5 Balki M et al, Obstet Gynecol 2004 initial oxytocin dose (IU) LESS oxytocin IS MORE hemodynamic stability Changes in hemodynamics induced by a 5 IU oxytocin bolus • spinal anesthesia for cesarean delivery Pulse power analysis for hemodynamic assessment 20 •CO (L/min) 0 2000 •SVR (dyn.s.cm-5) 0 200 • BP (mm Hg) 0 150 • HR, SV (mL) 0 0 90 180 270 360 Archer TL et al, Int J Obstet Anesth 2008 delivery oxytocin time (s) Oxytocin in presence of hypovolemia: a disaster 5 IU 5 IU 200 180 160 120 100 80 60 40 blood pressure (mm Hg) (mm blood pressure 20 CEMD 1997-1999, RCOG Press 2000 0 Risks and complications associated with other uterotonics ® ® PGE2/sulproston (Nalador ), PGE1/misoprostol (Cytotec ) •SVR ↓ + CO ↑ ¾ hypotension, myocardial ischemia, arrhythmia … VF nausea, vomiting, diarrhea, shivering, fever • bronchoconstriction ® PGF2α (Minprostin F2α) withdrawn from market : PVR ↑ Ergot alkaloids (Methergin®) • hypertension, coronary artery spasm, myocardial ischemia • cerebral artery spasm, ischemic cerebral injury • bronchospasm ¾ contraindications: preeclampsia, hypertension … Vercauteren M et al, Acta Anaesthesiol Scand 2009 ‘Parturient’ Emil Knöll, Basel 1889-1972.
Load more

Recommended publications
  • Cord Prolapse
    CLINICAL PRACTICE GUIDELINE CORD PROLAPSE CLINICAL PRACTICE GUIDELINE CORD PROLAPSE Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and the Clinical Strategy and Programmes Division, Health Service Executive Version: 1.0 Publication date: March 2015 Guideline No: 35 Revision date: March 2017 1 CLINICAL PRACTICE GUIDELINE CORD PROLAPSE Table of Contents 1. Revision History ................................................................................ 3 2. Key Recommendations ....................................................................... 3 3. Purpose and Scope ............................................................................ 3 4. Background and Introduction .............................................................. 4 5. Methodology ..................................................................................... 4 6. Clinical Guidelines on Cord Prolapse…… ................................................ 5 7. Hospital Equipment and Facilities ....................................................... 11 8. References ...................................................................................... 11 9. Implementation Strategy .................................................................. 14 10. Qualifying Statement ....................................................................... 14 11. Appendices ..................................................................................... 15 2 CLINICAL PRACTICE GUIDELINE CORD PROLAPSE 1. Revision History Version No.
    [Show full text]
  • Molecular Basis of Ligand Recognition and Activation of Human V2 Vasopressin Receptor
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427077; this version posted January 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular basis of ligand recognition and activation of human V2 vasopressin receptor Fulai Zhou1, 12, Chenyu Ye2, 12, Xiaomin Ma3, 12, Wanchao Yin1, Qingtong Zhou4, Xinheng He1, 5, Xiaokang Zhang6, 7, Tristan I. Croll8, Dehua Yang1, 5, 9, Peiyi Wang3, 10, H. Eric Xu1, 5, 11, Ming-Wei Wang1, 2, 4, 5, 9, 11, Yi Jiang1, 5, 1. The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China 2. School of Pharmacy, Fudan University, Shanghai 201203, China 3. Cryo-EM Centre, Southern University of Science and Technology, Shenzhen 515055, China 4. School of Basic Medical Sciences, Fudan University, Shanghai 200032, China 5. University of Chinese Academy of Sciences, 100049 Beijing, China 6. Interdisciplinary Center for Brain Information, The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; 7. Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China 8. Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK 9. The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, China 10. Department of Biology, Southern University of Science and Technology, Shenzhen 515055, China 11. School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China 12. These authors contributed equally: Fulai Zhou, Chenyu Ye, and Xiaomin Ma.
    [Show full text]
  • Tractocile, Atosiban
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tractocile 6.75 mg/0.9 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of 0.9 ml solution contains 6.75 mg atosiban (as acetate). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless solution without particles. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Tractocile is indicated to delay imminent pre-term birth in pregnant adult women with: regular uterine contractions of at least 30 seconds duration at a rate of 4 per 30 minutes a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of 50% a gestational age from 24 until 33 completed weeks a normal foetal heart rate 4.2 Posology and method of administration Posology Treatment with Tractocile should be initiated and maintained by a physician experienced in the treatment of pre-term labour. Tractocile is administered intravenously in three successive stages: an initial bolus dose (6.75 mg), performed with Tractocile 6.75 mg/0.9 ml solution for injection, immediately followed by a continuous high dose infusion (loading infusion 300 micrograms/min) of Tractocile 37.5 mg/5 ml concentrate for solution for infusion during three hours, followed by a lower dose of Tractocile 37.5 mg/5 ml concentrate for solution for infusion (subsequent infusion 100 micrograms/min) up to 45 hours. The duration of the treatment should not exceed 48 hours. The total dose given during a full course of Tractocile therapy should preferably not exceed 330.75 mg of atosiban.
    [Show full text]
  • Tocolytics Used As Adjunctive Therapy at the Time of Cerclage Placement: a Systematic Review
    Journal of Perinatology (2015) 35, 561–565 © 2015 Nature America, Inc. All rights reserved 0743-8346/15 www.nature.com/jp ORIGINAL ARTICLE Tocolytics used as adjunctive therapy at the time of cerclage placement: a systematic review J Smith1,2 and EA DeFranco3,4 OBJECTIVE: To review the published literature on whether the use of empiric perioperative tocolytic medications could provide additional benefit when used in combination with cerclage. STUDY DESIGN: Systematic review of published medical literature reporting the efficacy of empiric tocolytics used as a perioperative adjunct to vaginal cerclage in high-risk patients. A PubMed search without date criteria of various tocolytics and cerclage yielded 42 studies. Review articles were excluded, as were reports of abdominal cerclage, emergent cerclage, or cerclage for the purpose of delayed interval delivery in twin gestations. RESULT: Only five publications on the topic of perioperative tocolytic use at the time of history or ultrasound-indicated vaginal cerclage placement were identified. These included zero clinical trials, three retrospective cohort studies, one case series and one case report. Only one cohort study compared cerclage with indomethacin and cerclage without indomethacin and suggested no difference between the groups. The other two published cohort studies had no referent group who received cerclage without tocolysis. One case series and one case report were also published reporting cerclage with empiric beta-mimetic and progesterone adjunctive therapy. CONCLUSION: There is a paucity of published data on the topic of adjunctive perioperative tocolytics with cerclage. Adequately powered clinical trials on perioperative use of tocolysis with cerclage compared with a standard cerclage placement alone are needed to establish efficacy.
    [Show full text]
  • Largescale Synthesis of Peptides
    Lars Andersson1 Lennart Blomberg1 Large-Scale Synthesis of Martin Flegel2 Ludek Lepsa2 Peptides Bo Nilsson1 Michael Verlander3 1 PolyPeptide Laboratories (Sweden) AB, Malmo, Sweden 2 PolyPeptide Laboratories SpoL, Prague, Czech Republic 3 PolyPeptide Laboratories, Inc., Torrance, CA, 90503 USA Abstract: Recent advances in the areas of formulation and delivery have rekindled the interest of the pharmaceutical community in peptides as drug candidates, which, in turn, has provided a challenge to the peptide industry to develop efficient methods for the manufacture of relatively complex peptides on scales of up to metric tons per year. This article focuses on chemical synthesis approaches for peptides, and presents an overview of the methods available and in use currently, together with a discussion of scale-up strategies. Examples of the different methods are discussed, together with solutions to some specific problems encountered during scale-up development. Finally, an overview is presented of issues common to all manufacturing methods, i.e., methods used for the large-scale purification and isolation of final bulk products and regulatory considerations to be addressed during scale-up of processes to commercial levels. © 2000 John Wiley & Sons, Inc. Biopoly 55: 227–250, 2000 Keywords: peptide synthesis; peptides as drug candidates; manufacturing; scale-up strategies INTRODUCTION and plants,5 have all combined to increase the avail- ability and lower the cost of producing peptides. For For almost half a century, since du Vigneaud first many years, however, the major obstacle to the suc- presented his pioneering synthesis of oxytocin to the cess of peptides as pharmaceuticals was their lack of world in 1953,1 the pharmaceutical community has oral bioavailability and, therefore, relatively few pep- been excited about the potential of peptides as “Na- tides reached the marketplace as approved drugs.
    [Show full text]
  • Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia
    A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 Edited by: Lian L.M., Kamarudin A., Siti Fauziah A., Nik Nor Aklima N.O., Norazida A.R. With contributions from: Hafizh A.A., Lim J.Y., Hoo L.P., Faridah Aryani M.Y., Sheamini S., Rosliza L., Fatimah A.R., Nour Hanah O., Rosaida M.S., Muhammad Radzi A.H., Raman M., Tee H.P., Ooi B.P., Shamsiah S., Tan H.P.M., Jayaram M., Masni M., Sri Wahyu T., Muhammad Yazid J., Norafidah I., Nurkhodrulnada M.L., Letchumanan G.R.R., Mastura I., Yong S.L., Mohamed Noor R., Daphne G., Kamarudin A., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Omar I., Zoriah A., Fong Y.Y.A., Nusaibah A.R., Feisul Idzwan M., Ghazali A.K., Hooi L.S., Khoo E.M., Sunita B., Nurul Suhaida B.,Wan Azman W.A., Liew H.B., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Asmah J., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I., Ghazali I., Wan Abu Bakar Y., Wan Hamilton W.H., Ravichandran J., Zaridah S., Wan Zahanim W.Y., Kannappan P., Intan Shafina S., Tan A.L., Rohan Malek J., Selvalingam S., Lei C.M.C., Ching S.L., Zanariah H., Lim P.C., Hong Y.H.J., Tan T.B.A., Sim L.H.B, Long K.N., Sameerah S.A.R., Lai M.L.J., Rahela A.K., Azura D., Ibtisam M.N., Voon F.K., Nor Saleha I.T., Tajunisah M.E., Wan Nazuha W.R., Wong H.S., Rosnawati Y., Ong S.G., Syazzana D., Puteri Juanita Z., Mohd.
    [Show full text]
  • Indomethacin in Pregnancy: Applications and Safety
    Original Article 175 Indomethacin in Pregnancy: Applications and Safety Gael Abou-Ghannam, M.D. 1 Ihab M. Usta, M.D. 1 Anwar H. Nassar, M.D. 1 1 Department of Obstetrics and Gynecology, American University of Address for correspondence and reprint requests Anwar H. Nassar, Beirut Medical Center, Hamra, Beirut, Lebanon M.D., American University of Beirut Medical Center, P.O. Box 113-6044/B36, Hamra 110 32090, Beirut, Lebanon (e-mail: [email protected]). Am J Perinatol 2012;29:175–186. Abstract Preterm labor (PTL) is a major cause of neonatal morbidity and mortality worldwide. Among the available tocolytics, indomethacin, a prostaglandin synthetase inhibitor, has been in use since the 1970s. Recent studies have suggested that prostaglandin synthetase inhibitors are superior to other tocolytics in delaying delivery for 48 hours and 7 days. However, increased neonatal complications including oligohydramnios, Keywords renal failure, necrotizing enterocolitis, intraventricular hemorrhage, and closure of the ► indomethacin patent ductus arteriosus have been reported with the use of indomethacin. Indometh- ► tocolysis acin has been also used in women with short cervices as well as in those with idiopathic ► preterm labor polyhydramnios. This article describes the mechanism of action of indomethacin and its ► short cervix clinical applications as a tocolytic agent in women with PTL and cerclage and its use in ► polyhydramnios the context of polyhydramnios. The fetal and neonatal side effects of this drug are also ► fetal side effects summarized and guidelines for its use are proposed. Preterm labor (PTL) is a major cause of neonatal morbidity in women with PTL and cerclage and its use in the context of and mortality worldwide.1 Care of premature infants has polyhydramnios.
    [Show full text]
  • Hemmo Pharmaceuticals Private Limited
    Global Supplier of Quality Peptide Products Hemmo Pharmaceuticals Private Limited Corporate Presentation Privileged & Confidential Privileged & Confidential Corporate Overview Privileged & Confidential 2 Company at a glance • Commenced operations in 1966 as a Key Highlights trading house, focusing on Oxytocin amongst other products Amongst the largest Indian peptide manufacturing company • In 1979, ventured into manufacturing of Oxytocin Competent team of 154 people including 6 PhDs, 60+ chemistry graduates/post graduates and 3 engineers • Privately held family owned company Portfolio – Generic APIs, Custom Peptides for Research and Clinical Development and Peptide • Infrastructure Fragments − State of art manufacturing facility in Developed 21 generic products in-house. Navi Mumbai, 5 more in progress − R&D facilities at Thane and Spain − Corporate office at Worli First and the only independent Indian company to have a US FDA approved peptide manufacturing site Privileged & Confidential 3 Transition from a trading house to a research based manufacturing facility Commenced Commenced Investment in State of the Art Opened R& D Expanded operations manufacturing greenfield project facility at Navi Centre in manufacturing as a trading of peptides intended for Mumbai Girona,Spain capacity House regulated markets commissioned R&D center set up in Infrastructure Mumbai 1966 1979 2005 2007 2008 2010 2011 2012 2014 2015 Oxytocin Oxytocin Desmopressin Buserelin Triptorelin Goserelin Linaclotide Glatiramer amongst Gonadorelin Decapeptide Cetrorelix
    [Show full text]
  • Oxytocin Receptor OXTR
    Oxytocin Receptor OXTR The oxytocin receptor belongs to the G-protein-coupled seven-transmembrane receptor superfamily. Its main physiological role is regulating the contraction of uterine smooth muscle at parturition and the ejection of milk from the lactating breast. The oxytocin receptors are activated in response to binding oxytocin and a similar nonapeptide, vasopressin. Oxytocin receptor triggers Gi or Gq protein-mediated signaling cascades leading to the regulation of a variety of neuroendocrine and cognitive functions. Oxytocin is a nonapeptide of the neurohypophyseal protein family that binds specifically to the oxytocin receptor to produce a multitude of central and peripheral physiological responses. In vivo, oxytocin acts as a paracrine and/or autocrine mediator of multiple biological effects. These effects are exerted primarily through interactions with G-protein-coupled oxytocin/vasopressin receptors, which, via Gq and Gi, stimulate phospholipase C-mediated hydrolysis of phosphoinositides. www.MedChemExpress.com 1 Oxytocin Receptor Agonists & Antagonists Atosiban Atosiban acetate (RW22164; RWJ22164) Cat. No.: HY-17572 (RW22164 acetate; RWJ22164 acetate) Cat. No.: HY-17572A Atosiban (RW22164; RWJ22164) is a nonapeptide Atosiban acetate (RW22164 acetate;RWJ22164 competitive vasopressin/oxytocin receptor acetate) is a nonapeptide competitive antagonist, and is a desamino-oxytocin analogue. vasopressin/oxytocin receptor antagonist, and is a Atosiban is the main tocolytic agent and has the desamino-oxytocin analogue. Atosiban is the main potential for spontaneous preterm labor research. tocolytic agent and has the potential for spontaneous preterm labor research. Purity: 99.09% Purity: 99.92% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Carbetocin Epelsiban Cat.
    [Show full text]
  • Tocolytic Therapy a Meta-Analysis and Decision Analysis
    Tocolytic Therapy A Meta-Analysis and Decision Analysis David M. Haas, MD, MS, Thomas F. Imperiale, MD, Page R. Kirkpatrick, Robert W. Klein, Terrell W. Zollinger, DrPH, and Alan M. Golichowski, MD, PhD OBJECTIVE: To determine the optimal first-line tocolytic ing prostaglandin inhibitors, only 80 would deliver within agent for treatment of premature labor. 48 hours, compared with 182 for the next-best treatment. METHODS: We performed a quantitative analysis of ran- CONCLUSION: Although all current tocolytic agents domized controlled trials of tocolysis, extracting data on were superior to no treatment at delaying delivery for maternal and neonatal outcomes, and pooling rates for both 48 hours and 7 days, prostaglandin inhibitors were each outcome across trials by treatment. Outcomes were superior to the other agents and may be considered the delay of delivery for 48 hours, 7 days, and until 37 weeks; optimal first-line agent before 32 weeks of gestation to adverse effects causing discontinuation of therapy; absence delay delivery. of respiratory distress syndrome; and neonatal survival. We (Obstet Gynecol 2009;113:585–94) used weighted proportions from a random-effects meta- analysis in a decision model to determine the optimal first-line tocolytic therapy. Sensitivity analysis was per- reterm birth, defined as any birth before the gesta- formed using the standard errors of the weighted propor- Ptional age of 37 weeks, is responsible for most of the 1–3 tions. neonatal morbidity and mortality in the United States and consumes 35% of all U.S. healthcare spending on RESULTS: Fifty-eight studies satisfied the inclusion crite- 4 ria.
    [Show full text]
  • < MOH Approved Drugs List >
    Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 1 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph. System : GASTRO-INTESTINAL SYSTEM 1 Main Group : ANTACIDS 1 Sub Group : ALUMINIUM COMPOUNDS 1 03000000105 ALUMINIUM HYDROXIDE GEL, DRIED 475 MG. CAPSULE Desirable Cat_C Not H/C Item 2 Sub Group : ANTACID COMPOUND PREPARATIONS 2 02000000079 ANTACID SUSPENSION (ALUMINIUM HYDROXIDE + BOTTLE Desirable MAGNESIUM HYDROXIDE OR TRISILICATE) 100 - 200 Cat_A ML. B0TTLE. H/C Item 3 03000000173 ANTACID TABLET (ALUMINIUM HYDROXIDE + TABLET/CAP Desirable MAGNESIUM HYDROXIDE OR TRISILICATE). Cat_A H/C Item 2 Main Group : ANTISPASMODICS 1 Sub Group : ANTIMUSCARINICS 4 01000000304 HYOSCINE N BUTYLBROMIDE 20MG/ML. 1ML. AMPOULE Essantial Cat_A H/C Item 5 03000000640 HYOSCINE N BUTYL BROMIDE 10MG. TABLET/CAP Essantial Cat_A H/C Item 6 020D0000063 ANTISPASMODIC DROPS 15ML-25ML. BOTTLE Desirable Cat_C Not H/C Item 2 Sub Group : OTHER ANTISPASMODIC AND MOTILITY STIMULANT 7 03000001245 MEBEVERINE HYDROCHLORIDE 100 MG - 135 MG. TABLET/CAP Essantial Cat_B Not H/C Item Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 2 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph.
    [Show full text]
  • List of Pharamaceutical Peptides Available from ADI
    List of Pharamaceutical Peptides Available from ADI ADI has highly purified research grade/pharma grade pharmaceutical peptides available for small research scale or in bulk (>Kg scale). (See Details at the website) http://4adi.com/commerce/catalog/spcategory.jsp?category_id=2704 Catalog# Product Description Catalog# Product Description PP-1000 Abarelix (Acetyl-Ser-Leu-Pro-NH2; MW:1416.06) PP-1410 Growth Hormone-releasing factor, GRF (human) PP-1010 ACTH 1-24 (Adrenocorticotropic Hormone human) Acetate PP-1420 Hexarelin PP-1020 Alarelin Acetate PP-1430 Histrelin Acetate PP-1030 Angiotensin PP-1440 Lepirudin PP-1040 Angiotensin II Acetate PP-1450 Leuprolide PP-1050 Antide Acetate PP-1460 Leuprorelin Acetate PP-1060 Argipressin Acetate PP-1470 Lipopeptide Acetate PP-1070 Argireline Acetate PP-1480 Lypressin PP-1080 Atosiban Acetate PP-1490 Lysipressin Acetate PP-1090 Aviptadil PP-1500 Matrixyl Acetate PP-1100 Bivalirudin Trifluoroacetate PP-1510 Melanotan I, Acetate PP-1110 Buserelin acetate PP-1520 Melanotan II, MT-II, Acetate PP-1120 Copaxone acetate (Glatiramer acetate) PP-1530 Mechano Growth Factor, MGF, TFA PP-1130 Carbetocin acetate PP-1540 Nafarelin Acetate PP-1140 Cetrorelix Acetate PP-1550 Nesiritide Acetate PP-1150 Corticotropin-releasing factor, CRF (human, rat) Acetate PP-1560 Octreotide Acetate PP-1160 Corticotropin-releasing factor, CRF (ovine) PP-1570 Ornipressin Acetate Trifluoroacetate PP-1580 Oxytocin Acetate PP-1170 Deslorelin Acetate PP-1590 Palmitoyl Pentapeptide PP-1180 Desmopressin Acetate PP-1610 Pentagastrin Ammonium
    [Show full text]